GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Thanks for posting the article. The crux of it is this excerpt:

>>
…it's not clear yet that Symphogen's technique will pass regulatory authorities' standards for consistency. “The authorities are going to ask them to characterize the antibodies individually,” says Yann Echelard, vice president of R&D at GTC Biotherapeutics in Framingham, Massachusetts. If they can't put the same amount of each antibody into every dose, “that's a showstopper for getting approved,” he says.
<<

If GTC had a long road to regulatory approval for its production platform, it’s reasonable to assume that the polyclonal companies will encounter a longer road.

Moreover, for a variety of practical reasons, animal serum does not begin to compare to milk as a source for therapeutic proteins.